Novartis Pharmaceutical Corp. scored a victory in injury litigation over its bone-building drug Reclast when a federal court rejected a plaintiff’s bid to offer key expert testimony (Jones v. Novartis Pharm. Corp., N.D. Ala., No. 2:13-cv-00624, 1/26/17).
The ruling hobbles efforts by plaintiff Ernesteen Jones to continue her suit claiming the osteoporosis medication Reclast caused her to suffer femur fractures in both legs.
Expert testimony is crucial in pharmaceutical injury cases in proving a causal link between the defendant’s product and the plaintiff’s injury.
Five expert witnesses were either barred or saw their proposed testimony greatly restricted after ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.